Results 281 to 290 of about 151,900 (300)

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

Cancer Cell
Xiufeng Pang, Guizhen Zhou, Kewen Hu
exaly  

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer

Annals of Oncology, 2013
Thierry Lecomte, David Tougeron, J M Tourani   +2 more
exaly  

A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

Annals of Oncology, 2011
Dongyun Yang, E K Rowinsky
exaly  

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

Cancer Cell
Hongbin Ji, Juntao Gao, Khrystyna Myndzar   +2 more
exaly  

KRAS

openaire   +1 more source

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

Cancer Cell
Caicun Zhou, Chuchu Shao, Libo Luo
exaly  

KRAS G12C INHIBITORS

2019
BLAKE JAMES F, BURGESS LAURENCE E, CHICARELLI MARK JOSEPH, CHRISTENSEN JAMES GAIL, COOK ADAM, FELL JAY BRADFORD, FISCHER JOHN P, MARX MATTHEW ARNOLD, MEJIA MACEDONIO J, SAVECHENKOV PAVEL, VIGERS GUY P A, SMITH CHRISTOPHER RONALD, RODRIGUEZ MARTHA E   +12 more
openaire   +6 more sources

A first-in-class EGFR-directed KRAS G12V selective inhibitor

Cancer Cell
Chad V Pecot, Alessandro Porrello, Salma H Azam   +2 more
exaly  

Kra...

2001
openaire   +1 more source

Kra

Punkt: Almanach Gdańskich Środowisk Twórczych, 1979
openaire